Julian Bergier has a degree in Biotechnology, a researcher from Conicet and a member of the
Laboratory of Genetic Engineering and Cellular and Molecular Biology at the University of Quilmes. From there in 2016, it was proposed to investigate, together with other professionals, the development of a
biosensor for the detection of viral pathogens. "It was the time of an outbreak of Dengue in the north of the country, where there is no staff, or diagnostic centers to meet the demand of the diagnosis in a context of disease expansion", and this was the point starting point for the construction of a rapid detection platform for microorganisms that we call d3 (DNA Diagnostic Device, or DNA diagnostic device).
After carrying out the development and presenting it in congresses, they contacted different places to see if they could develop detection systems for other diseases of interest, associated with the veterinary area and human health. "We knew that one of the main characteristics of the platform we had built was that it could be used for the detection of other microorganisms," said Bergier, and in this way the project to develop a
fast device for detection from
Chlamydia trachomatis (d3 POC) a sexually transmitted bacterium that affects more than 127 million people in the world according to data from the World Health Organization.
According to the researchers, the contribution of this device can have an impact on public health because the technology developed and used in this system
allows to detect the DNA of a pathogen in less than an hour and the cost per reaction is significantly lower than current systems. "In addition, it does not require expensive equipment, but a portable and rechargeable sensor device, controlled by an application in a
. These characteristics allow us to dispense with specialized technical personnel, and highly complex laboratories, "says Bergier.
The massive implementation of this device allows the patient to attend the doctor or primary care rooms and if he has a chlamydial symptom, the doctor can take a sample of the patient and analyze it with the d3 (Dna Diagnostic Device) device. The result is obtained in the course of approximately 1 hour, and the same treatment can be started if you have a positive diagnosis.
Towards its clinical validation
The project is in the clinical validation stage, that is to say, panels of samples already identified are being analyzed to study their performance. Until the date of the date they obtained 100% agreement regarding the current reference technology (real-time PCR). Now, they continue to expand the sample analysis to include different system parameters.
The development was carried out in conjunction with
LEBYM, a clinical analysis laboratory of Entre Ros, and the project is a finalist in the competition
Samsung Innova in the health area. "With my work group we imagine the creation of a company dedicated to diagnosis, which uses this platform for the development of different rapid detection systems. We aim to offer, in our country and the region, biotechnological tools for the diagnosis area. that collaborate in the democratization of health, "adds Bergier. The private diagnostic market will be one of the first customers and then bet that the provincial or municipal states use it.
One of the things that most excites Bergier's team is that the project was born of scientists trained in the country, uses local inputs and provides a solution to a major health problem. "This chain, from the generation of knowledge to its application to a real problem, is very difficult to achieve in our country -details-, and we consider that it is one of the valuable contributions that we can give from the scientific field to society" .
Developed in the country the portable device d3 (t) that diagnoses a sexually transmitted disease – LA NACION